Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03437486 · ClinicalTrials.gov registry record
Mechanisms of Familial Pulmonary Fibrosis
A clinical trial of Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 750
- Enrollment target
- 1
- Study location
NCT03437486: Recruiting study of Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis, sponsored by Vanderbilt University Medical Center.
NCT03437486 is a study of Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 750 participants, roughly in line with the 737-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03437486, a study of Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form of idiopathic pulmonary fibrosis (IPF), which is defined as 2 or more bloodline relatives which have a diagnosis of idiopathic interstitial pneumonia (IIP). The most common form of idiopathic interstitial pneumonia in FIP families is IPF (approximately 70%). The inheritance pattern in FIP is consistent with autosomal dominant inheritance with incomplete penetrance. Therefore, individuals in this study have approximately 50% risk of carrying a disease-associated allele. The causative gene is currently only known approximately 20% of families. The main goal of this longitudinal study is to better establish the natural history of FIP and to identify risk factors for later development of symptomatic disease. The investigators' plan is to follow these at-risk individuals with yearly questionnaires and planned in person 2 year follow-ups through age 75 or until they develop symptomatic FIP.
Primary Outcome
by ATS/ERS criteria
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2009-01-01 |
| Est. Completion | 2030-01-30 |
What NCT03437486 shows while recruiting
NCT03437486 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 737-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target.
The record links to 3 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT03437486 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03437486 about?
NCT03437486 is a clinical study titled "Mechanisms of Familial Pulmonary Fibrosis". This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form of idiopathic pulmonary fibrosis (IPF), which is defined as 2 or more bloodline relatives which have a diagnosis of idiopathic interstitial...
What is the current status of trial NCT03437486?
This trial is currently recruiting. The enrollment target is 750 participants. The study started on 2009-01-01. Estimated completion is 2030-01-30.
What conditions does trial NCT03437486 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Familial Interstitial Pneumonia.
Who is sponsoring clinical trial NCT03437486?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03437486 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03437486's enrollment target sits among peer trials
750 9th of 51 higher than 43 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI